Home › Cancer (all types) › NCT05427240

eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer

A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* 18 years of age or older
* Speak and understand English
* Male or Female
* No prior germline genetic testing
* Meet current National Comprehensive Cancer Network (NCCN) guidelines for germline genetic testing

Exclusion Criteria:

-Communication difficulties such as:

* Uncorrected or uncompensated hearing and/or vision impairment
* Uncorrected or uncompensated speech defects
* Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

About the study

This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are replaced with a self-directed web-based eHealth intervention to provide critical data to inform optimal ways to deliver clinical genetic testing in eligible individuals, while maintaining quality of care and favorable cognitive, affective and behavioral outcomes.

What is being tested

• Pre-Test Intervention (other)
• Standard of Care (other)
• Post-Test Intervention (other)

Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 1,000 · Started: Sep 28, 2022

Contact the study team

• Angela R Bradbury, MD · Phone: 215 615 3341
• Dominique Fetzer, BA · Phone: 215 662 2753

Official record on ClinicalTrials.gov — NCT05427240

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.